In the wake of the U.S. Supreme Court’s decision in Amgen Inc. v. Sanofi, 598 U.S. 594 (2023) (Amgen), in which the Court addressed whether Amgen’s functional antibody genus claims satisfy the ...

Regarding the OX40 target itself, Amgen’s view is that targeting the OX40 receptor is better and Sanofi believes that targeting the OX40 ligand is better. The two approaches were not ...

The first one in the U.S., Amgen's (AMGN) Amjevita ... Meanwhile, Dupixent from Regeneron and Sanofi is set to bring in $13.5B this year, up from $11.6B in 2023. The drug is set to gain from ...

Sanofi SNY announced that the FDA has approved the label expansion ... The SNY drug is also approved in combination with Amgen’s Kyprolis (carfilzomib) and dexamethasone for treating patients with ...

Amgen and AstraZeneca have hopes for their asthma ... Additionally, Regeneron and Sanofi have a second COPD candidate in IL-33 inhibitor itepekimab, which is being tested in two phase 3 trials.

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Graham Parry has given his Buy rating due to a combination of factors including the underwhelming efficacy of competitor Amgen’s rocatinlimab compared to Sanofi’s Dupixent and upcoming ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National ... Morgan Stanley backs Overweight on Regeneron after Amgen temporarily enjoined Closing Bell Movers: Micron rallies ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target ...